Mayo Foundation for Medical Education and Research

Zymogenetics, Inc.

Ares Trading S.a.

Stephen M Ansell

Anne J Novak

Richard L Ehman

Eric Sievers

Kiaran P McGee

Herve Broly

Jun Chen

Sharon J Busby

Arnaud Ythier

Yogesh K Mariappan

Ivan Nestorov

Jan Öhrström

A system and method for determining a response of a tumor following a chemotherapy process includes the use of a magnetic resonance elastography (MRE) driver and a magnetic resonance imaging (MRI) system. The method includes controlling the MRE driver and the MRI system to acquire raw MRE data from the tumor, inverting the raw MRE data to produce an elastogram of the tumor, and determining a response of the tumor to the chemotherapy process from the elastogram.

System and method for assessing response to chemotherapy using magnetic resonance elastography

The present invention provides an isolated polynucleotide comprising at least one polymorphic nucleotide sequence, for example, the major alleles of the SNPs described as rs12583006, rs1224141, and rs1248930 and diagnostic assays for detecting the presence of these polymorphism associated with a condition associated with BLyS activity, such as hematological malignancy including B cell malignancies. The diagnostic assays are useful in predicting an individual's likelihood of developing a condition associated with BLyS activity, such as hematological malignancies, and for methods for treating an individual clinically diagnosed with a condition associated with BLyS activity, such as prediction of a patient's likelihood to respond to a specific drug treatment. The invention also provides an array of nucleic acid molecules immobilized on a solid surface, where at least one of the nucleic acid molecules comprises a BLyS polymorphic nucleic acid molecule. The nucleic acid arrays of the invention allow rapid detection of hybridizing nucleic acid-molecules, in a nucleic acid sample from an individual, of a BLyS polymorphism associated with hematological malignancy.

Polymorphisms of the BLyS gene and use in diagnostic methods

The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.

Methods for treating B-cell malignancies using a TACI-Ig fusion molecule

The present invention provides an isolated polynucleotide comprising at least one polymorphic nucleotide sequence, for example, at position &#x2212;871 from the promoter region of the BLyS gene, and diagnostic assays for detecting the presence of this polymorphism associated with a condition associated with BLyS activity, such as hematological malignancy including B cell malignancies. The diagnostic assays are useful in predicting an individual's likelihood of developing a condition associated with BLyS activity, such as hematological malignancies, and for methods for treating an individual clinically diagnosed with a condition associated with BLyS activity, such as prediction of a patient's likelihood to respond to a specific drug treatment. The invention also provides an array of nucleic acid molecules immobilized on a solid surface, where at least one of the nucleic acid molecules comprises a BLyS polymorphic nucleic acid molecule. The nucleic acid arrays of the invention allow rapid detection of hybridizing nucleic acid-molecules, in a nucleic acid sample from an individual, of a BLyS polymorphism associated with hematological malignancy.

Promoter polymorphisms of the BLyS gene and use in diagnostic methods

Growing community of inventors

Rochester, MN, United States of America

Stephen M Ansell